This study is looking into whether intravenous (IV) albumin (a protein found in blood) can improve thinking and memory problems in people with cirrhosis (scarring of the liver) and hepatic encephalopathy (HE, a brain disorder caused by liver disease). Researchers want to see if these improvements last for several weeks after albumin infusions stop. You might be able to join if you are over 18, have cirrhosis, and have experienced HE. The study will measure changes in your cognitive function using a test called the Psychometric Hepatic Encephalopathy Score (PHES) to see if albumin is effective. The study status is currently unclear.

Study design

This is a single-arm, single-blind study, meaning all 30 participants will receive both albumin and saline, and you won't know which you're getting at a given time. You will act as your own control, comparing your results during the albumin phase to the saline phase.

What's involved

You will receive IV 25% albumin and IV saline over an 8-week period. This will involve biological sampling and cognitive and health-related quality of life testing.

Compensation

Not stated in the trial record.

Follow-up

Your cognitive function will be measured at 4 weeks after both the placebo and albumin phases.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.